Financials Salarius Pharmaceuticals, Inc.
Equities
SLRX
US79400X3052
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4951 USD | -0.78% | +0.41% | -23.83% |
Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
Mar. 25 | Top Premarket Gainers | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 15.33 | 21.66 | 22.4 | 3.486 | 2.56 | 2.136 | - |
Enterprise Value (EV) 1 | 15.33 | 21.66 | 22.4 | 3.486 | 2.56 | 2.136 | 2.136 |
P/E ratio | - | -1.82 x | -1.6 x | - | -0.17 x | -0.02 x | -0.02 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 4.42 x | 4.14 x | 12.2 x | - | - | - | - |
EV / Revenue | 4.42 x | 4.14 x | 12.2 x | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | -1,323,976 x | - | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 162 | 952 | 1,808 | 2,278 | 3,938 | 4,314 | - |
Reference price 2 | 94.50 | 22.75 | 12.39 | 1.530 | 0.6500 | 0.4951 | 0.4951 |
Announcement Date | 3/23/20 | 3/18/21 | 3/10/22 | 3/27/23 | 3/22/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 3.465 | 5.233 | 1.84 | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -7.786 | - | - | - | -22.11 | -23.21 |
Operating Margin | - | -148.78% | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | -12.77 | - | - | - | - |
Net income 1 | - | -7.352 | -12.77 | -31.61 | -12.54 | -21.88 | -23 |
Net margin | - | -140.49% | -693.84% | - | - | - | - |
EPS 2 | - | -12.50 | -7.750 | - | -3.840 | -26.81 | -23.48 |
Free Cash Flow | -11.58 | - | - | - | - | - | - |
FCF margin | -334.2% | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/18/21 | 3/10/22 | 3/27/23 | 3/22/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | -3.742 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT | -3.747 | -4.145 | - | - | - | - | -5.421 | -3.971 | -2.532 | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -3.737 | -4.105 | - | - | - | - | -5.341 | - | - | - | - | - | - | - |
Net income | -3.737 | -4.105 | -6.109 | -4.718 | -14.41 | -6.371 | -5.341 | -3.877 | -2.443 | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -2.000 | -2.250 | -3.250 | -2.250 | -6.410 | -2.750 | -2.230 | -1.430 | -0.6500 | -6.700 | -6.700 | -6.700 | -6.710 | -5.850 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 3/10/22 | 5/12/22 | 8/5/22 | 11/10/22 | 3/27/23 | 5/11/23 | 8/10/23 | 11/9/23 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | -11.6 | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/18/21 | 3/10/22 | 3/27/23 | 3/22/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.83% | 2.14M | |
+1.51% | 42.75B | |
+48.20% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SLRX Stock
- Financials Salarius Pharmaceuticals, Inc.